ClinicalTrials.gg
CompletedNCT04938453Updated Jul 17, 2023Results posted

A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg Capsule

A Phase 1 interventional study of nintedanib 25 mg and nintedanib 100 mg in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-17.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main objective of this trial is to investigate the relative bioavailability of 100 mg nintedanib given as four capsules of 25 mg nintedanib compared with one capsule of 100 mg nintedanib.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 55 years (inclusive)
  • (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
  • Signed and dated written prior to admission to the study, in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    nintedanib 4 X 25 mg (T) then nintedanib 1 X 100 mg (R))

    first test (T), then reference (R) treatment

    Drug: nintedanib 25 mg · Drug: nintedanib 100 mg

  • Experimental
    nintedanib 1 X 100 mg (R) then nintedanib 4 X 25 mg (T)

    first reference (R), then test (T) treatment

    Drug: nintedanib 25 mg · Drug: nintedanib 100 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of the nintedanib in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported.

    Time frame: For both arms: Within 3 hours (h) before and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, 34 h, 48 h and 72h after nintedanib administration.

  2. Maximum Measured Concentration of Nintedanib in Plasma (Cmax)

    Maximum measured concentration of nintedanib in plasma (Cmax) is reported.

    Time frame: For both arms: Within 3 hours (h) before and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, 34 h, 48 h and 72h after nintedanib administration.

Secondary outcomes

  1. Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported.

    Time frame: For both arms: Within 3 hours (h) before and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, 34 h, 48 h and 72h after nintedanib administration.

07

Results

Posted Jul 17, 2023

Participant flow

This was a phase I trial to test the relative bioavailability of 100 milligram (mg) nintedanib (Ofev®) given as four capsules of 25 mg compared to one capsule of 100 mg following oral administration in healthy male subjects (an open-label, randomised, single-dose, two-period, two-sequence crossover study).

Period 1
Participant flow — Period 1
MilestoneNintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T)Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R)
Started1010
Completed1010
Not completed00
Washout Period 1
Participant flow — Washout Period 1
MilestoneNintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T)Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R)
Started1010
Completed99
Not completed11
Withdrew: Adverse event10
Withdrew: Physician decision01
Period 2
Participant flow — Period 2
MilestoneNintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T)Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R)
Started99
Completed99
Not completed00

Outcome measures

PrimaryArea Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of the nintedanib in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported.

Time frame:
For both arms: Within 3 hours (h) before and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, 34 h, 48 h and 72h after nintedanib administration.
Reported as:
Geometric least squares mean · hours (h) *nanogram(ng)/milliliter (mL)
Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hours (h) *nanogram(ng)/milliliter (mL)Nintedanib 1 X 100 mg (R)Nintedanib 4 X 25 mg (T)
Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)150.65 ± NA148.34 ± NA
Statistical analysis
  • Nintedanib 1 X 100 mg (R) vs Nintedanib 4 X 25 mg (T) · Ratio of glsms (%): 98.47 · 90% CI 90.87 to 106.69Ratio of Geometric Least Squares Means (GLSMs) was calculated as (GLSM of "nintedanib 4 X 25 mg")/(GLSM of "nintedanib 1 X 100 mg"). Standard error of the mean is actually intra-individual geometric coefficient of variation (gCV \[%\]).
PrimaryMaximum Measured Concentration of Nintedanib in Plasma (Cmax)

Maximum measured concentration of nintedanib in plasma (Cmax) is reported.

Time frame:
For both arms: Within 3 hours (h) before and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, 34 h, 48 h and 72h after nintedanib administration.
Reported as:
Geometric least squares mean · nanogram (ng)/milliliter (mL)
Maximum Measured Concentration of Nintedanib in Plasma (Cmax)
nanogram (ng)/milliliter (mL)Nintedanib 1 X 100 mg (R)Nintedanib 4 X 25 mg (T)
Maximum Measured Concentration of Nintedanib in Plasma (Cmax)15.23 ± NA15.27 ± NA
Statistical analysis
  • Nintedanib 1 X 100 mg (R) vs Nintedanib 4 X 25 mg (T) · Ratio of glsms (%): 100.29 · 90% CI 85.05 to 118.24Ratio of Geometric Least Squares Means (GLSMs) was calculated as (GLSM of "nintedanib 4 X 25 mg")/(GLSM of "nintedanib 1 X 100 mg"). Standard error of the mean is actually intra-individual geometric coefficient of variation (gCV \[%\]).
SecondaryArea Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported.

Time frame:
For both arms: Within 3 hours (h) before and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, 34 h, 48 h and 72h after nintedanib administration.
Reported as:
Geometric least squares mean · hours * nanogram/milliliter
Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hours * nanogram/milliliterNintedanib 1 X 100 mg (R)Nintedanib 4 X 25 mg (T)
Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)157.55 ± NA155.85 ± NA
Statistical analysis
  • Nintedanib 1 X 100 mg (R) vs Nintedanib 4 X 25 mg (T) · Ratio of glsms (%): 98.92 · 90% CI 91.35 to 107.12Ratio of Geometric Least Squares Means (GLSMs) was calculated as (GLSM of "nintedanib 4 X 25 mg")/(GLSM of "nintedanib 1 X 100 mg"). Standard error of the mean is actually intra-individual geometric coefficient of variation (gCV \[%\]).

Adverse events

Collected over For both arms: From drug administration until 14 days thereafter.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib 1 X 100 mg (R)0/19 (0%)0/19 (0%)10/19 (52.6%)
Nintedanib 4 X 25 mg (T)0/19 (0%)0/19 (0%)5/19 (26.3%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventNintedanib 1 X 100 mg (R)Nintedanib 4 X 25 mg (T)
DiarrhoeaGastrointestinal disorders3/194/19
Abdominal painGastrointestinal disorders2/190/19
Abdominal pain upperGastrointestinal disorders2/191/19
NauseaGastrointestinal disorders2/191/19
ConstipationGastrointestinal disorders0/191/19
FlatulenceGastrointestinal disorders1/190/19
GastritisGastrointestinal disorders1/190/19
NasopharyngitisInfections and infestations1/190/19
SunburnInjury, poisoning and procedural complications1/190/19
Decreased appetiteMetabolism and nutrition disorders1/190/19

Baseline characteristics

Treated set (TS): TS included all subjects who were randomised and treated with at least 1 dose of the investigational medicinal product.

Age, Continuous
Age, Continuous(Years)Nintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T)Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R)Total
Mean35.2 ± 10.132.4 ± 7.833.8 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Nintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T)Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R)Total
Female000
Male101020
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T)Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R)Total
Hispanic or Latino000
Not Hispanic or Latino101020
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T)Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101020
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Aug 2021, 1 month.

Results were first posted in Jul 2023, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2021
First posted
Jun 24, 2021
StartActual
Jul 14, 2021
Primary completionActual
Aug 30, 2021
CompletionActual
Aug 30, 2021
Results first posted
Jul 17, 2023
Last update
Jul 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04938453
Responsible party
Sponsor
First posted
Jun 24, 2021
Start date
Jul 14, 2021
Primary completion
Aug 30, 2021
Completion
Aug 30, 2021
Results posted
Jul 17, 2023
Last update
Jul 17, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion